drtimos.bsky.social
@drtimos.bsky.social
LucidQuest YouTube > Trending in Oncology: BLA filed for EGFRm NSCLC, TGCT NDA and more: Oncology saw progress fortnight: sevabertinib earned dual Breakthrough Therapy tags for first-line HER2-mutant NSCLC, Atossa received a Study May Proceed letter for… Subscribe for more! #LucidQuest #PharmaCI
Trending in Oncology: BLA filed for EGFRm NSCLC, TGCT NDA and more
Oncology saw progress fortnight: sevabertinib earned dual Breakthrough Therapy tags for first-line HER2-mutant NSCLC, Atossa received a Study May Proceed letter for oral Z-endoxifen in ER-positive, HER2-negative metastatic breast cancer, and Curadel’s CPI-008 gained US and EU orphan status for pancreatic cancer imaging. Pfizer’s BREAKWATER reported 64 percent ORR for Braftovi plus cetuximab plus FOLFIRI versus 39 percent for standard therapy in BRAF V600E mCRC. Summit filed an ivonescimab BLA, Eureka’s ECT204 secured RMAT, Merck’s pimicotinib NDA advanced, and Tahoe–Alloy launched an AI-ADC joint venture.
www.youtube.com
January 19, 2026 at 5:03 PM
Signal or noise? > Asus confirms it will ‘no longer’ make Android smartphones
as it shifts focus to AI >> Comment below! #healthtech #AI #industry40 #IoT #mhealth
Asus confirms it will ‘no longer’ make Android smartphones as it shifts focus to AI
Asus has reiterated that it will “no longer” be making “new” Android smartphones with its focus shifting towards the market built up by AI. more…
dlvr.it
January 19, 2026 at 4:45 PM
🚀 #ATS2025 buzz check! #COPD, #Asthma & #Pulmonology dominate, with #Data (~21%) & #Efficacy (~18%) driving talk. 82% positive vibes on AI & therapy breakthroughs. 📊🫁 Dive into our full report! http://dlvr.it/TQRMpy #SocialListening #LucidQuest #ATS25 @atscommunity @ATS_AII
ATS_2025_Social_Media_Report_by_LucidQuest.pdf
dlvr.it
January 19, 2026 at 3:58 PM
Signal or noise? > AGC Biologics Celebrates U.S. and EU Approval of Fondazione
Telethon’s Waskyra™ Treatment for Wiskott-Aldrich Syndrome -
BioSpace >> Comment below! #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #healthcare #competitivemarketing #biotech
AGC Biologics Celebrates U.S. and EU Approval of Fondazione Telethon’s Waskyra™ Treatment for Wiskott-Aldrich Syndrome - BioSpace
AGC Biologics Celebrates U.S. and EU Approval of Fondazione Telethon’s Waskyra™ Treatment for Wiskott-Aldrich Syndrome  BioSpace
dlvr.it
January 19, 2026 at 3:30 PM
Oncology in 2025 was about execution at scale: earlier-line ambition, ADCs becoming portfolio-defining, and delivery models that health systems can sustain. Clinical impact now depends on deployability. 👉 Read more http://dlvr.it/TQRJks #LucidQuest
Oncology 2025 Review: Curative-Intent Expansion, ADC Acceleration, and the Operationalization of Immunotherapy - LucidQuest Ventures
A 2025 oncology review, covering trial readouts, regulatory activity, safety and delivery innovations, diagnostics, and 2026 catalysts.
dlvr.it
January 19, 2026 at 3:02 PM
Signal or noise? > Aneurin Bevan University Health Board rolls out Clinisys
WinPath >> Comment below! #mhealth #healthtech #IoT #AI #industry40
Aneurin Bevan University Health Board rolls out Clinisys WinPath
The Blood Transfusion service at Aneurin Bevan University Health Board (ABUHB) has gone live with Clinisys WinPath.
dlvr.it
January 19, 2026 at 2:57 PM
Signal or noise? > Makary cites higher FDA user fees as one key to counter
China biotech - Endpoints News >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #competitivemarketing #biotech #pharma
Makary cites higher FDA user fees as one key to counter China biotech - Endpoints News
Makary cites higher FDA user fees as one key to counter China biotech  Endpoints News
dlvr.it
January 19, 2026 at 2:30 PM
LucidQuest Views >>> Public Health Video Recap—January 16, 2025 Comment below! #LucidQuest #PharmaCI
Public Health Video Recap—January 16, 2025
This Public Health video recap highlights major population health and preventive care developments, spanning cancer outcomes, mental health, aging, infectious […] The post Public Health Video Recap—January 16, 2025 appeared first on LucidQuest Ventures.
dlvr.it
January 19, 2026 at 1:52 PM
Signal or noise? > Polar OS 5 update adds dark maps, RPE grading and new
widgets >> Comment below! #industry40 #mhealth #healthtech #IoT #AI
Polar OS 5 update adds dark maps, RPE grading and new widgets
Multiple alarms, RPE workout scoring and map enhancements are just some of the updates landing with Polar OS 5. The The post Polar OS 5 update adds dark maps, RPE grading and new widgets appeared first on Gadgets & Wearables.
dlvr.it
January 19, 2026 at 1:36 PM
Signal or noise? > Immunology biotech Agomab, eye-focused SpyGlass are latest
biotechs to share IPO ambitions >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #competitivemarketing #pharma #biotech
Immunology biotech Agomab, eye-focused SpyGlass are latest biotechs to share IPO ambitions
Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both unveiled their intentions to go public, in the latest sign that the IPO window is reopening in 2026.
dlvr.it
January 19, 2026 at 12:30 PM
Signal or noise? > Sony Xperia 1 IV and Xperia 5 IV gain LineageOS 23.0
support >> Comment below! #IoT #healthtech #AI #mhealth #industry40
Sony Xperia 1 IV and Xperia 5 IV gain LineageOS 23.0 support
While availability of Sony Xperia handsets has dwindled over the last couple of years, those with the Xperia 1 and Xperia 5 IV might be happy to hear that LineageOS support is now available for the hardware. more…
dlvr.it
January 19, 2026 at 11:48 AM
Signal or noise? > AstraZeneca to acquire China rights for AbelZeta’s CAR-T
therapy - Pharmaceutical Technology >> Comment below! #strategy #competitiveintelligence #marketing #biotech #pharma #healthcare #pharmaceutical #competitivemarketing
AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapy - Pharmaceutical Technology
AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapy  Pharmaceutical Technology
dlvr.it
January 19, 2026 at 10:30 AM
Signal or noise? > OpenAI to start testing ads in ChatGPT >> Comment below! #healthtech #AI #IoT #mhealth #industry40
OpenAI to start testing ads in ChatGPT
(Telecompaper) OpenAI announced plans to start testing advertising in ChatGPT. This will start in the US in the coming weeks, in the free version and entry-level Go subscription of ChatGPT...
dlvr.it
January 19, 2026 at 10:27 AM
🚀 Big buzz at #ASGCT25: #GeneEditing & #CRISPR headlines, 20% data-driven talk, 85% positive vibes on breakthrough therapies for #DMD & #rarediseases!🧬 Download our full #socialmedia report! http://dlvr.it/TQR1yw #GeneTherapy #SocialListening #LucidQuest
@ASGCTherapy @ESGCT
January 19, 2026 at 10:19 AM
Signal or noise? > Anthropic and Google follow OpenAI to launch healthcare
AI >> Comment below! #healthtech #IoT #industry40 #mhealth #AI
Anthropic and Google follow OpenAI to launch healthcare AI
Anthropic and Google are the latest major players to announce AI tools designed for healthcare, following the launch of ChatGPT Health.
dlvr.it
January 19, 2026 at 10:00 AM
Hematology in 2025 converged on MRD-anchored depth, fixed-duration momentum, and deliverability at scale. Outpatient feasibility, cycle time, and CRS/ICANS rates shaped adoption across regions. 👉 Read more http://dlvr.it/TQQzTw #LucidQuest
Hematology 2025 Review: Deeper Responses, Faster Translation, and the Push to Scale - LucidQuest Ventures
Hematology 2025 review of pivotal trial readouts, global regulatory approvals, safety and delivery considerations, and more key updates.
dlvr.it
January 19, 2026 at 9:27 AM
AI in healthcare 2025 became infrastructure: end-to-end workflows, trust and governance as gates, AI treated as a regulated asset. Screening scale, autonomous triage, and faster reviews proved it. 👉 Read more http://dlvr.it/TQQyxH #LucidQuest
Artificial Intelligence in Healthcare 2025 Review: From Pilot Tools to Operating Infrastructure - LucidQuest Ventures
2025 review of how artificial intelligence reshaped healthcare delivery, diagnostics, drug development, regulation, and decision-making.
dlvr.it
January 19, 2026 at 9:12 AM